目的 探讨依折麦布片联合瑞舒伐他汀钙片治疗低密度脂蛋白胆固醇未达标的急性冠状动脉综合征的临床疗效。方法 选取2015年11月—2016年11月青岛市中心医院收治的98例低密度脂蛋白胆固醇未达标的急性冠状动脉综合征患者作为研究对象，按照随机数字表法将患者随机分为对照组和治疗组，每组各49例。对照组睡前口服瑞舒伐他汀钙片，10 mg/d；治疗组在对照组治疗的基础上睡前口服依折麦布片，10 mg/d。两组患者均连续治疗3个月。观察两组患者的临床疗效，同时比较治疗前后两组的血脂水平、超敏C反应蛋白（hs-CRP）、颈动脉粥样斑块积分、血管内皮功能指标和主要心血管事件（MACE）随访情况。结果 治疗后，治疗组总有效率为93.88%，明显高于对照组的79.59%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者总胆固醇（TC）、三酰甘油（TG）和低密度脂蛋白胆固醇（LDL-C）水平明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组TC、TG和LDL-C水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者hs-CRP和颈动脉粥样斑块积分均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组hs-CRP和颈动脉粥样斑块积分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者内皮素-1（ET-1）明显降低，一氧化氮（NO）明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组血管内皮功能指标水平显著优于对照组，两组比较差异具有统计学意义（P<0.05）。随访1年后，两组MACE发生率分别为31.9%、10.2%，两组比较差异具有统计学意义（P<0.05）。结论 依折麦布片联合瑞舒伐他汀钙片治疗低密度脂蛋白胆固醇未达标的急性冠状动脉综合征患者疗效显著，可明显降低血脂和炎症因子水平，改善血管内皮功能和颈动脉斑块积分，减少主要心血管事件的发生，且安全性好，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Ezetimibe Tablets combined with Rosuvastatin Calcium Tablets in treatment of acute coronary syndrome with low-density lipoprotein cholesterol not reached the standard. Methods Patients (98 cases) with acute coronary syndrome with low-density lipoprotein cholesterol not reached the standard in Qingdao Center Hospital from November 2015 to November 2016 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were po administered with Rosuvastatin Calcium Tablets before bedtime, 10 mg/d. Patients in the treatment group were po administered with Ezetimibe Tablets 10 mg/d on the basis of the control group. Patients in two groups were treated for 3 months.After treatment, the clinical efficacy was evaluated, and the blood lipid levels, hs-CRP, carotid atherosclerotic plaque score, vascular endothelial function indexes, and MACE in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 93.88%, which was significantly higher than 79.59% in the control group, and there were differences between two groups (P<0.05). After treatment, TC, TG, and LDL-C levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, TC, TG, and LDL-C levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, hs-CRP and carotid atherosclerotic plaque score in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, hs-CRP and carotid atherosclerotic plaque score in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, levels of ET-1 in two groups were significantly decreased, but the levels of NO in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the vascular endothelial function indexes levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After follow-up for 1 year, MACE incidences of the two groups were 31.9% and 10.2%, respectively, and there were differences between two groups (P<0.05). Conclusion Ezetimibe Tablets combined with Rosuvastatin Calcium Tablets has significant curative effect on acute coronary syndrome with low-density lipoprotein cholesterol not reached the standard, can significantly reduce blood lipid and inflammatory factor levels, improve vascular endothelial function and carotid artery plaque score, and reduce the occurrence of MACE, with good security, which has a certain clinical application value.